RWLK - ReWalk Robotics Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1600
-0.0100 (-0.32%)
As of 11:49AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close 3.1700
Open 3.2000
Bid 3.1700 x 1300
Ask 3.1900 x 1200
Day's Range 3.1000 - 3.2299
52 Week Range 2.4600 - 26.7500
Volume 32,343
Avg. Volume 1,069,812
Market Cap 23.034M
Beta (3Y Monthly) 2.02
PE Ratio (TTM) N/A
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    ReWalk Robotics Reports Second Quarter 2019 Financial Results

    — 2019 second quarter total revenue of $0.9 million — — Received FDA & CE clearance for ReStore Exo-Suit — YOKNEAM ILIT, Israel / MARLBOROUGH, Mass., Aug. 08, 2019 --.

  • GlobeNewswire

    ReWalk Robotics to Report Second Quarter 2019 Financial Results on August 8, 2019

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Aug. 06, 2019 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its.

  • GlobeNewswire

    ReWalk Robotics Announces Closing of Registered Direct Offering for $5.0 Million Priced At-the-Market

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced the closing of its previously announced registered direct offering of approximately 833,334 ordinary shares at a purchase price of $6.00 per ordinary share, priced at-the-market. ReWalk also issued unregistered warrants to purchase up to 416,667 ordinary shares. The warrants have a term of 5.5 years, are exercisable immediately and have an exercise price of $6.00 per ordinary share.

  • GlobeNewswire

    ReWalk Robotics Announces Pricing of Registered Direct Offering for $5 Million

    YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., June 10, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced that it has entered into definitive agreements with institutional investors providing for the issuance of approximately 833,334 ordinary shares at a purchase price of $6.00 per ordinary share in a registered direct offering priced at-the-market. ReWalk will also issue unregistered warrants to purchase up to approximately 416,667 ordinary shares. The warrants will have a term of 5.5 years, be exercisable immediately following the issuance date and have an exercise price of $6.00 per ordinary share.

  • GlobeNewswire

    ReWalk Robotics Announces Exercise of Warrants Resulting in Cash Proceeds of $10.8 Million

    YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., June 05, 2019 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), today announced the agreement by several.

  • FDA Issues Clearance for the ReStore™ Exo-Suit, the First Soft Robotic System for Stroke Therapy
    PR Newswire

    FDA Issues Clearance for the ReStore™ Exo-Suit, the First Soft Robotic System for Stroke Therapy

    New age innovation offers versatile, affordable medical device to U.S. rehab clinics to treat millions of patients with gait impairment MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, June 4, 2019 /PRNewswire/ ...

  • ReWalk Robotics Receives CE Mark for ReStore™ Exo-Suit Stroke Rehabilitation Device
    PR Newswire

    ReWalk Robotics Receives CE Mark for ReStore™ Exo-Suit Stroke Rehabilitation Device

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, May 29, 2019 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company"), a manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced that the ReStore Exo-Suit for stroke rehabilitation has received CE marking, clearing it for sale to rehabilitation clinics in the European Union. "The ReStore revolutionizes post stroke gait training, providing key advantage to clinics, therapists and patients," said ReWalk CEO Larry Jasinski. The company announced that ReStore will be priced significantly lower than the first generation of rigid exoskeleton technologies, and can be used to treat a broad range of stroke rehabilitation patients.  ReWalk will offer direct purchase and third party leasing programs for the ReStore in the EU.

  • GlobeNewswire

    ReWalk Robotics Appoints Chunlin (Allen) Han to its Board of Directors

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or “the Company”) announced today that the Company has appointed Mr. Chunlin (Allen) Han to the board of directors of the Company (the “Board”). Ms. Ning Cong has departed the Board as of May 14, 2019 and Mr. Han has been appointed to ReWalk Board as of May 15, 2019 pursuant to the investment agreement with Timwell Corporation Limited (“Timwell”). Mr. Han is an executive director of Liquid Harmony Limited and serves as Head of Investment and Financing for Realcan Pharmaceutical Group Co. Ltd. (002589.SZ), a large distributor of medical drugs and equipment in China with access to more than 8,000 hospitals and 33,000 primary medical institutions, where he has been instrumental in acquiring more than 50 distribution companies and participated in three joint venture investments.

  • GlobeNewswire

    ReWalk Robotics Reports First Quarter 2019 Financial Results

    — 2019 first quarter total revenue of $1.6 million — — Gross margin record of 59% — — On track with ReStore Exo-Suit launch timeline — YOKNEAM ILIT, Israel and.

  • GlobeNewswire

    ReWalk Robotics to Report First Quarter 2019 Financial Results on May 7, 2019

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, May 03, 2019 -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) today announced that the Company will release its.

  • GlobeNewswire

    ReWalk Robotics Regains Compliance with Nasdaq Listing Rules 5550(a) and 5550(b)

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced that it has regained compliance with Nasdaq Listing Rules 5550(b) (“Rule 5550(b)”) and 5550(a)(2) (“Rule 5550(a)(2)”). As previously reported on November 1, 2018, the Company received a notification letter from Nasdaq on October 26, 2018 stating that, under Nasdaq Listing Rule 5550(b), the Company failed to comply with the minimum $35 million market value of listed securities requirement for continued listing on The Nasdaq Capital Market as of October 26, 2018 and did not meet the rule’s alternative $2.5 million shareholders’ equity and $500,000 net income standards as of applicable balance sheet and income statement dates.

  • ReWalk Announces Regional Blue Cross Blue Shield Plan Beneficiaries Are Winning Requests to Walk Again
    PR Newswire

    ReWalk Announces Regional Blue Cross Blue Shield Plan Beneficiaries Are Winning Requests to Walk Again

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 25, 2019 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company"), announced today that an independent reviewer has declared the ReWalk Personal 6.0 Exoskeleton medically necessary for a paralyzed Mississippi woman. This marks the 17th ReWalk System reimbursed under a regional Blue Cross Blue Shield plan. In 2018 ReWalk adopted a patient-based reimbursement submission process which leverages elements of the U.S. Patient Protection and Affordable Care Act, including the right to have ReWalk appeal a coverage denial on a patient's behalf before independent medical review boards.

  • GlobeNewswire

    ReWalk Robotics to Present at the ThinkEquity Conference on May 2nd

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 23, 2019 -- ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief.

  • ReWalk Announces First Personal Exoskeleton Provided to Cigna Beneficiary
    PR Newswire

    ReWalk Announces First Personal Exoskeleton Provided to Cigna Beneficiary

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 16, 2019 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company"), announced today that the first Cigna Corporation (Cigna) insurance beneficiary has received a ReWalk Personal 6.0 exoskeleton for use at home and in his community. The beneficiary is a New York man who sustained a spinal cord injury in a motorcycle accident in 2016. After learning about ReWalk's technology and going through the proper examinations, he became eligible to receive a ReWalk Personal 6.0 exoskeleton.

  • GlobeNewswire

    ReWalk Robotics Announces Closing of Registered Direct Offering for $4.25 Million Priced At-the-Market

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced the closing of its previously announced registered direct offering of approximately 816,914 ordinary shares at a purchase price of $5.2025 per ordinary share, priced at-the-market. ReWalk also issued unregistered warrants to purchase up to 408,457 ordinary shares. The warrants have a term of 5.5 years, are exercisable immediately and have an exercise price of $5.14 per ordinary share.

  • GlobeNewswire

    ReWalk Robotics Announces Pricing of Registered Direct Offering for $4,250,000

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced that it has entered into definitive agreements with institutional investors providing for the issuance of approximately 816,914 ordinary shares at a purchase price of $5.2025 per ordinary share in a registered direct offering priced at-the-market. ReWalk will also issue unregistered warrants to purchase up to approximately 408,457 ordinary shares. The warrants will have a term of 5.5 years, be exercisable immediately following the issuance date and have an exercise price of $5.14 per ordinary share.

  • ACCESSWIRE

    Will Your Insurance Pay for a ReWalk Robotics Solution for Paralysis?

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on ReWalk Robotics, Ltd. (RWLK), a company that develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury (SCI) or stroke. There is a substantial market for the company's ReWalk exoskeleton for SCI patients in the U.S. with a substantial backlog of demand. On March 26, 2019, the company announced the delivery of a ReWalk Personal 6.0 System to Lucy Dodd, a British children's social care worker paralyzed by a rare spinal condition, which will allow her to stand and walk again.

  • GlobeNewswire

    ReWalk Robotics Completes One-for-Twenty-Five Reverse Share Split

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) reported today that it has completed the reverse share split of ReWalk ordinary share at a ratio of one-for-twenty-five shares, which will take effect on April 1, 2019. The Company also increased its authorized and registered share capital and amended its Articles of Association to reflect the reverse share split and the increase in share capital. Following the reverse share split and increase in authorized share capital, the total number of ordinary shares that the Company is authorized to issue will be 60 million shares, the par value per share of the ordinary shares will be NIS 0.25 and the authorized share capital of the Company will be NIS 15 million.

  • PR Newswire

    British Paraplegic Receives ReWalk Exoskeleton Device After Successful Campaign to Walk Again

    BIRMINGHAM, England and YOKNEAM ILIT, Israel, March 26, 2019 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced delivery of a ReWalk Personal 6.0 System to Lucy Dodd, a British children's social care worker paralyzed by a rare spinal condition, which will allow her to stand and walk again. The ReWalk exoskeleton—a medical device designed for individuals with spinal cord injury to be used in the home and the community—is in use throughout the UK and around the world. The system is being delivered following a successful fundraising campaign, led by Dodd and supported by the Association for the Independence of Disabled People (AID), a small Cumbrian charity which aims to improve accessibility in society for the disabled.

  • GlobeNewswire

    ReWalk Robotics Announces Closing of $4.37 Million Public Offering

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced the closing and funding of its previously announced public offering of 19,000,000 ordinary shares at a price to the public of $0.23 per share. ReWalk intends to use the net proceeds from the offering for (i) sales, marketing and reimbursement expenses related to market development activities and broadening third-party payor coverage and (ii) research and development costs related to, in the shorter term, its ReStore™ exo-suit designed to assist patients who have had a stroke, and, in the longer term, expansion of the Company’s technological platform to address other medical indications affecting the ability to walk. A shelf registration statement on Form S-3 (Registration No. 333-209833) relating to the public offering of the ordinary shares described above was filed by the Company with the Securities and Exchange Commission (the “SEC”) and was declared effective on May 9, 2016.

  • GlobeNewswire

    ReWalk Robotics Announces Pricing of $4.37 Million Public Offering of Ordinary Shares

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced the pricing of a public offering of 19,000,000 ordinary shares, offered at a price to the public of $0.23 per share, for gross proceeds of approximately $4.37 million, before deducting placement agent fees and other estimated offering expenses payable by ReWalk. The offering is expected to close on or about February 25, 2018, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The offering is being conducted as a “best efforts” offering and the placement agent is not obligated to purchase any securities.

  • GlobeNewswire

    ReWalk Robotics Announces Proposed Public Offering of Ordinary Shares

    ReWalk Robotics Ltd. (RWLK) (“ReWalk” or the “Company”) today announced that it intends to offer and sell, subject to market and other conditions, its ordinary shares in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The offering is being conducted as a “best efforts” offering and the placement agent is not obligated to purchase any securities.

  • ReWalk Announces 510k FDA Submission for ReStore™ Exo-Suit for Stroke Rehabilitation
    PR Newswire

    ReWalk Announces 510k FDA Submission for ReStore™ Exo-Suit for Stroke Rehabilitation

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Feb. 19, 2019 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical devices for individuals with lower limb disabilities, today announced the submission of its 510k application to the U.S. Food and Drug Administration (FDA) for the ReStore™ exo-suit for gait training during stroke rehabilitation. Strokes are a major cause of serious long-term disability, with over 795,000 people suffering a stroke each year in the U.S. alone. The soft, garment-like design allows variability of movement in combination with first-of-its-kind active ankle assistance that adaptively synchronizes with the patient's natural gait, to facilitate functional gait training activities.

  • ReWalk Announces Cigna as First Private U.S. Insurer to Adopt National Policy Change for Coverage of Personal Exoskeleton Devices
    PR Newswire

    ReWalk Announces Cigna as First Private U.S. Insurer to Adopt National Policy Change for Coverage of Personal Exoskeleton Devices

    MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Feb. 13, 2019 /PRNewswire/ -- ReWalk Robotics, Ltd. (RWLK) ("ReWalk" or the "Company"), disclosed today that Cigna Corporation, a leading global health service company, has revised its policy regarding coverage of exoskeleton medical devices for persons with spinal cord injury (SCI). Cigna, which previously had a non-coverage policy, will now review submissions from beneficiaries on a case-by-case basis to consider providing coverage based on medical criteria. This policy revision is the first of its kind by a major private insurer for individuals eligible to use exoskeleton devices.

  • GlobeNewswire

    ReWalk Robotics Reports Fourth Quarter 2018 Financial Results

    — 2018 total revenue of $6.5 million and $1.6 million during the fourth quarter of 2018 —— Preparing for 2019 commercial launch of ReStore for stroke patients — YOKNEAM ILIT,.